$RGNX has been mentioned 17 times over the past 12 months by 2 FinTwit voices, with the first mention on October 8, 2025. Biotech-focused analyst @adamfeuerstein dominates discussion with 16 mentions, while @investmentguru_ contributed 1 mention. The most recent activity centered on FDA regulatory developments in June 2026, with @adamfeuerstein noting both a reversal and subsequent resubmission of the company's Duchenne gene therapy program.

Discussion of $RGNX has focused on its AAV gene therapy platform and late-stage pipeline programs. @adamfeuerstein reported on FDA regulatory momentum, while @investmentguru_ positioned the company within a broader framework of gene therapy as foundational infrastructure in healthcare, alongside its partnership with AbbVie on a potential non-rare disease indication in wet AMD. The company's retinal and Duchenne programs were noted as precision-targeted by genetic subtype rather than blanket indications.